Global Swine Vaccines Market Report 2022: Focus on Products (Recombinant, Inactivated) and Type (Pseudorabies, Porcine Circovirus Type 2) – Forecast to 2028 –

DUBLIN–(BUSINESS WIRE)–The “Swine Vaccines Market Size, Share and Trends Analysis Report 2021-2028” has been added to from offer.

The global swine vaccines market size is expected to reach USD 2.09 billion by 2028, registering a CAGR of 4.9%

Rising disease prevalence, increasing demand for animal protein, and growing R&D expenditure for vaccine innovation are driving the growth of the market. Porcine parvovirus (PPV), porcine reproductive and respiratory syndrome (PRRS), porcine circovirus type 2 (PCV2), foot-and-mouth disease, classical swine fever and others remain extremely prevalent diseases in pig farms, resulting in economic losses.

The COVID-19 pandemic has had a direct or indirect impact on the businesses, operating results and financial conditions of market participants. The Animal Health business faced various production and supply bottlenecks due to the COVID-19 pandemic; these are delays in the delivery of raw materials and active ingredients and capacity constraints in the transport of goods (particularly air and sea). While on the other side, the industry has expanded its research at an unprecedented rate in animal health. Thus, the COVID-19 pandemic has had a significant impact on the growth of the market.

Moreover, growing investments by key players to develop advanced products for better diagnosis are likely to propel the growth of the market. For example, in May 2020, Indian Immunologicals Ltd. introduced the vaccine against classical swine fever. Stating that he introduced the product under the brand name “Raksha Class”. It is a unique vaccine based on cell culture technology developed in cooperation with the Indian Veterinary Research Institute, Bareilly.

Key players are involved in strategic initiatives, such as joint ventures, mergers, acquisitions, and new product launches to gain higher market share.

For example, in February 2020, the new vaccine created by ICAR, Indian Veterinary Research Institute (IVRI), based in Uttar Pradesh, was much cheaper than an already existing vaccine. It costs only 2 rupees for each dose compared to the current vaccine rate of 15-20 rupees for each dose and an imported Korean vaccine rate of 30 rupees for each dose.

Highlights of the Swine Vaccines Market Report

  • Inactivated vaccines segment dominated the market in 2020 due to its easy availability and low cost compared to others

  • A recombinant vaccine is expected to register the fastest CAGR over the forecast period due to the benefits, such as increased efficacy, technological advancements and increased long-term prevention

  • The porcine circovirus type 2 segment dominated the market in 2020 owing to the increased prevalence of the disease. Moreover, it is the rapid mutation of all single-stranded DNA (ssDNA) viruses, so it has a high mutation and recombination rate.

  • Asia-Pacific is expected to register the fastest CAGR during the forecast period due to increasing cases of infectious diseases in pigs, increased animal health awareness, growing demand for animal protein and rapid urbanization

Main topics covered:

Chapter 1. Methodology and scope

Chapter 2. Executive Summary

Chapter 3. Market Variables, Trends and Scope

3.1. Market Line Prospects

3.1.1. Parent Market Outlook

3.1.2. Related/auxiliary market outlook

3.2. Mapping of penetration and growth prospects

3.3. Swine vaccine market dynamics

3.3.1. Market Driver Analysis

3.3.2. Market Restriction Analysis

3.4. Swine Vaccine Industry Analysis – Porter’s

3.5. Swine-PEST Vaccine Industry Analysis

3.6. Regulatory framework

Chapter 4. Impact of COVID-19 on the Swine Vaccines Market

4.1. Disease prevalence analysis

4.2. Impact of Covid-19 and future scenario

4.3. Strategies implemented by companies

4.4. Impact on market players

Chapter 5. Swine Vaccines Market: Type Estimates and Trend Analysis

5.1. Analysis of type movement and market share, 2020 and 2028

5.2. Market size and forecast and trend analysis, 2016 to 2028 for the following:

5.2.1. Swine flu

5.2.2. Classical swine fever

5.2.3. Porcine parvovirus

5.2.4. Porcine circovirus type 2

5.2.5. Mr. Hyo

5.2.6. Actinobacillus Pleuropneumonia

5.2.7. PRRS

5.2.8. Foot-and-mouth disease

5.2.9. Pseudorage

5.2.10. VEP

5.2.11. Others

Chapter 6. Swine Vaccines Market: Product Estimates and Trend Analysis

6.1. Analysis of product movement and market share, 2020 and 2028

6.2. Market size and forecast and trend analysis, 2016 to 2028 for the following:

6.2.1 Live attenuated vaccines

6.2.2 Inactivated vaccines

6.2.3 Subunit vaccines

6.2.4 DNA vaccines

6.2.5 Recombinant vaccines

Chapter 7. Swine Vaccines Market: Regional Estimates and Trend Analysis

7.1. Regional movement analysis and market share, 2020 and 2028

7.2. Market share analysis, by region

7.3. Market size and forecast and trend analysis, 2016 to 2028 for the following:

7.3.1. North America we Canada

7.3.2. Europe UK Germany France Italy Spain

7.3.3. Asia Pacific Japan China India

7.3.4. Latin America Brazil Mexico Argentina

7.3.5. Middle East and Africa South Africa Saudi Arabia

Chapter 8. Competitive Landscape

8.1. Categorization of Market Participation

8.2. Public enterprises

8.2.1. Company Market Share / Position Analysis

8.2.2. Heat map analysis

8.3. Private companies

8.3.1. List of key companies

Chapter 9. Business Profiles

9.1. Company presentation

9.2. Financial performance

9.3. Product Benchmarking

9.4. Strategic initiatives

  • Merck Animal Health

  • Ceva Animal Health

  • Zoetis

  • Boehringer Ingelheim GmbH

  • Elanco

  • Indian Immunologicals Ltd.

  • Bago biogenesis

  • Phibro Animal Health

  • Organic KM


For more information on this report, visit

Comments are closed.